Passa al contenuto
Merck
  • Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils.

Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils.

Proceedings of the National Academy of Sciences of the United States of America (2015-01-28)
Amy-Jo Casbon, Damien Reynaud, Chanhyuk Park, Emily Khuc, Dennis D Gan, Koen Schepers, Emmanuelle Passegué, Zena Werb
ABSTRACT

Expansion of myeloid cells associated with solid tumor development is a key contributor to neoplastic progression. Despite their clinical relevance, the mechanisms controlling myeloid cell production and activity in cancer remains poorly understood. Using a multistage mouse model of breast cancer, we show that production of atypical T cell-suppressive neutrophils occurs during early tumor progression, at the onset of malignant conversion, and that these cells preferentially accumulate in peripheral tissues but not in the primary tumor. Production of these cells results from activation of a myeloid differentiation program in bone marrow (BM) by a novel mechanism in which tumor-derived granulocyte-colony stimulating factor (G-CSF) directs expansion and differentiation of hematopoietic stem cells to skew hematopoiesis toward the myeloid lineage. Chronic skewing of myeloid production occurred in parallel to a decrease in erythropoiesis in BM in mice with progressive disease. Significantly, we reveal that prolonged G-CSF stimulation is both necessary and sufficient for the distinguishing characteristics of tumor-induced immunosuppressive neutrophils. These results demonstrate that prolonged G-CSF may be responsible for both the development and activity of immunosuppressive neutrophils in cancer.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Perossido di idrogeno, contains inhibitor, 30 wt. % in H2O, ACS reagent
Sigma-Aldrich
Perossido di idrogeno, 30 % (w/w) in H2O, contains stabilizer
Sigma-Aldrich
Hydriodic acid, 57 wt. % in H2O, distilled, stabilized, 99.95%
Sigma-Aldrich
Perossido di idrogeno, 50 wt. % in H2O, stabilized
Sigma-Aldrich
Perossido di idrogeno, 30% (w/w), puriss. p.a., reag. ISO, reag. Ph. Eur.
Sigma-Aldrich
Hydriodic acid, contains no stabilizer, ACS reagent, 55%
Sigma-Aldrich
Hydriodic acid, contains no stabilizer, distilled, 57 wt. % in H2O, 99.99% trace metals basis
Sigma-Aldrich
Perossido di idrogeno, contains ~200 ppm acetanilide as stabilizer, 3 wt. % in H2O
Sigma-Aldrich
Perossido di idrogeno, contains inhibitor, 35 wt. % in H2O
Sigma-Aldrich
Perossido di idrogeno, purum p.a., ≥35% (RT)
Sigma-Aldrich
Hydriodic acid, contains ≤1.5% hypophosphorous acid as stabilizer, ACS reagent, ≥47.0%
Millipore
Perossido di idrogeno, 3%, suitable for microbiology
Supelco
Perossido di idrogeno, ≥30%, for trace analysis
Sigma-Aldrich
Perossido di idrogeno, contains inhibitor, 30 wt. % in H2O, meets USP testing specifications
Sigma-Aldrich
Perossido di idrogeno, 34.5-36.5%
Sigma-Aldrich
Hydriodic acid, 57 wt. %, distilled, 99.999% trace metals basis
Supelco
Perossido di idrogeno, 30 % (w/w), for ultratrace analysis
Sigma-Aldrich
Perossido di idrogeno, tested according to Ph. Eur.